{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:47:23Z","timestamp":1773082043661,"version":"3.50.1"},"reference-count":45,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,1,21]],"date-time":"2018-01-21T00:00:00Z","timestamp":1516492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["17990 (L.L.K.)"],"award-info":[{"award-number":["17990 (L.L.K.)"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["508240 (H.J.K.)"],"award-info":[{"award-number":["508240 (H.J.K.)"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Because of the failure of many promising therapeutics identified in preclinical evaluation, funding sources have established guidelines for increased rigor in animal evaluations. The myasthenia gravis (MG) community of scientists has developed guidelines for preclinical assessment for potential MG treatments. Here, we provide a focused summary of these recommendations and the role of complement in disease development in experimental models of MG.<\/jats:p>","DOI":"10.1111\/nyas.13555","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T14:58:40Z","timestamp":1516633120000},"page":"136-142","source":"Crossref","is-referenced-by-count":20,"title":["Acetylcholine receptor antibody\u2013mediated animal models of myasthenia gravis and the role of complement"],"prefix":"10.1111","volume":"1413","author":[{"given":"Linda L.","family":"Kusner","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Physiology George Washington University School of Medicine and Health Sciences  Washington DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjistha","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Department of Neurology George Washington University School of Medicine and Health Sciences  Washington DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Department of Neurology George Washington University School of Medicine and Health Sciences  Washington DC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.10.042"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11556"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2011.04.012"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001489"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.13615","article-title":"Bias in the reporting of sex and age in biomedical research on mouse models","volume":"5","author":"Florez\u2010Vargas O.","year":"2016","journal-title":"Elife"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2015.05.001","article-title":"Editorial: special issue on standardization of preclinical evaluation of animal models for myasthenia gravis","volume":"270","author":"Kusner L.L.","year":"2015","journal-title":"Exp. Neurol."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.02.025"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.02.009"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2015.03.010"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.70"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12462"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2009.08.006"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.10.014"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109322200"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199701)20:1<92::AID-MUS12>3.0.CO;2-3"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.06.005"},{"key":"e_1_2_11_18_1","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end\u2010plate in myasthenia gravis. Ultrastructure and light microscopic localization and electrophysiological correlations","volume":"52","author":"Engel A.G.","year":"1977","journal-title":"Mayo Clin. Proc."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.6.1167"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-198003000-00005"},{"key":"e_1_2_11_21_1","first-page":"1755","volume-title":"Myology","author":"Engel A.G.","year":"2004"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.08.002"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(93)90103-N"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.12.1748"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23839"},{"key":"e_1_2_11_26_1","unstructured":"Alexion Pharma GmbH.2016. Alexion announces topline results from phase 3 REGAIN study of eculizumab (Soliris\u00ae) in patients with refractory generalized myasthenia gravis (GMG). Accessed September 8 2016.http:\/\/news.alexionpharma.com\/press-release\/product-news\/alexion-announces-topline-results-phase-3-regain-study-eculizumab-soliris."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.423"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2065-4"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403196200"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.147.4.973"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.7.3847"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.05.012"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.140.8.2589"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03198.x"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4657"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.142.8.2654"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(96)00144-0"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.12.8562"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21536"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23247"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.08.009"},{"key":"e_1_2_11_42_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrneph.2014.30","article-title":"Anaemia: mutations in C5 explain eculizumab resistance","volume":"10","author":"Razzak M.","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311084"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.10.014"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.01.003"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.144"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnyas.13555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.13555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:45:33Z","timestamp":1694616333000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.13555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,21]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/nyas.13555"],"URL":"https:\/\/doi.org\/10.1111\/nyas.13555","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,21]]}}}